SA
Create Free Alerts
ZBIOZBIONASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on March 16, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 235,700 shares of the Company's common stock (“Stock Options”) and an aggregate of 33,450 restricted stock units of the Company's common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees' entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com

Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 - - New, half-life extended anti-CD-19 and FcγRIIb mAb (ZB014) progressing toward clinical development - - Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis (MS) ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 - - Oral, IL-17AA/AF inhibitor (ZB021) Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data by year-end - - Up to $250 million non-dilutive, multi-tranche debt financing secured from Pharmakon - WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today reported financial results for the quarter and year ended December 31, 2025, and provided recent corporate updates.

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on February 17, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 35,700 shares of the Company's common stock (“Stock Options”) and an aggregate of 53,625 restricted stock units of the Company's common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees' entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management's presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 1:30 p.m. ET.

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 27.4% in January
defenseworld.net

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 27.4% in January

Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 6,086,840 shares, a growth of 27.4% from the December 31st total of 4,779,373 shares. Currently, 13.6% of the shares of the stock are sold short. Based on an average

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase 100,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity
defenseworld.net

Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity

Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) shares gapped up prior to trading on Monday after an insider bought additional shares in the company. The stock had previously closed at $16.08, but opened at $17.24. Zenas BioPharma shares last traded at $19.41, with a volume of 337,494 shares. Specifically, CEO Leon O. Moulder, Jr.

Leon Moulder, Jr. Acquires 20,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock
defenseworld.net

Leon Moulder, Jr. Acquires 20,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 20,000 shares of the business's stock in a transaction on Friday, January 9th. The shares were acquired at an average price of $16.55 per share, for a total transaction of $331,000.00. Following the completion of the acquisition, the chief executive officer directly

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance